Hepatic artery thrombosis: Conservative management or retransplantation?
Nigel D. Heaton – 10 September 2013
Justification for routine intensive care after liver transplantation
Michael Ramsay – 10 September 2013
De novo malignant disease after liver transplantation? Risk and surveillance strategies
Geoffrey W. McCaughan, Claire M. Vajdic – 10 September 2013
Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: A systematic review and meta‐analysis
Siddharth Singh, Jithinraj Edakkanambeth Varayil, Edward V. Loftus, Jayant A. Talwalkar – 10 September 2013 – Patients with primary sclerosing cholangitis (PSC) and associated inflammatory bowel disease (IBD) have an increased risk of colorectal cancer (CRC). We estimated the pooled incidence of CRC after liver transplantation (LT) in patients with PSC as well as in a subset of patients with associated IBD (PSC‐IBD). Through a systematic review of major bibliographic databases up to April 1, 2013, we identified cohort studies reporting the incidence of de novo CRC after LT for PSC.
Early allograft dysfunction: Causes, recognition, and management
Marc Deschenes – 10 September 2013
Outcomes for recipients of liver transplantation for alpha‐1‐antitrypsin deficiency–related cirrhosis
Elizabeth J. Carey, Vivek N. Iyer, Darlene R. Nelson, Justin H. Nguyen, Michael J. Krowka – 10 September 2013 – Alpha‐1‐antitrypsin (AAT) deficiency is a rare genetic disease caused by an abnormal production of the serine protease inhibitor AAT. Liver transplantation (LT) cures cirrhosis caused by AAT deficiency and restores the normal production of AAT. There are few reports on the post‐LT outcomes of patients with AAT deficiency. The aim of this study was to determine the characteristics and outcomes of patients undergoing LT for AAT deficiency at 3 large transplant centers.
Systematic investigation of elevated cholestatic enzymes during the third posttransplant month
Andrew L. Mason, Aldo J. Montano‐Loza – 10 September 2013
Painting the liver with lasers: The future of liver histology?
Diren Beyoğlu, Jeffrey R. Idle – 5 September 2013
Forkhead box Q1 promotes hepatocellular carcinoma metastasis by transactivating ZEB2 and VersicanV1 expression
Limin Xia, Wenjie Huang, Dean Tian, Lin Zhang, Xingshun Qi, Zhangqian Chen, Xin Shang, Yongzhan Nie, Kaichun Wu – 5 September 2013 – Forkhead box Q1 (FoxQ1) is a master regulator of tumor metastasis. However, the molecular mechanism of FoxQ1 in regulating hepatocellular carcinoma (HCC) metastasis remains unknown. Here we report a novel function for FoxQ1 in modifying the tumor microenvironment to promote HCC metastasis. FoxQ1 expression was an independent and significant risk factor for the recurrence and survival in two independent cohorts totaling 1,002 HCC patients.
Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry
Florian Douam, Viet Loan Dao Thi, Guillemette Maurin, Judith Fresquet, Dimitri Mompelat, Mirjam B. Zeisel, Thomas F. Baumert, François‐Loïc Cosset, Dimitri Lavillette – 4 September 2013 – Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 are important mediators for productive cell entry. However, knowledge about their structure, intra‐ or intermolecular dialogs, and conformational changes is scarce, limiting the design of therapeutic strategies targeting E1E2.